Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET

电话会议定于6月6日星期四下午5:30/东部时间上午8:30

SAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc., (NASDAQ: HALO) ('Halozyme') today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

圣地亚哥，2024年6月5日/PRNewswire/--Halozyme Therapeutics，Inc.（纳斯达克：HALO）（“Halozyme”）今天宣布授予欧洲专利号4269578，涵盖从Halozyme的ENHANZE®制造方法获得的ENHANZE®rHuPH20产品，该公司向其当前和未来的许可证持有人提供该产品。

The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029..

这项新专利是根据Halozyme的所有ENHANZE®许可证授予的。它将在37个欧洲国家得到验证，并于2029年3月6日到期。。

'This new European patent for ENHANZE further strengthens our robust patent estate and extends the durability of our portfolio,' said Dr. Helen Torley, president and chief executive officer of Halozyme. 'We are pleased to be able to maintain the original royalty rate for DARZALEX SC in Europe through March 2029 based on this new patent.'.

Halozyme总裁兼首席执行官海伦·托利（HelenTorley）博士说，ENHANZE的这项新欧洲专利进一步巩固了我们强大的专利地位，并延长了我们投资组合的耐久性基于这项新专利，我们很高兴能够在2029年3月之前维持DARZALEX SC在欧洲的原始版税。”。

Under the terms of Halozyme's ENHANZE® license with Janssen, the newly granted patent prevents the reduction in the royalty rate on sales of DARZALEX® SC in the European countries where it is validated until the patent expires. The new patent is not expected to have any impact to royalties under other ENHANZE® licenses with an issued or pending collaboration patent, as current royalty rates for these licenses are already expected to extend beyond expiration of the new patent. .

根据Halozyme与Janssen的ENHANZE®许可条款，新授予的专利可防止DARZALEX®SC在欧洲国家的销售版税降低，直到专利到期。新专利预计不会对其他ENHANZE®许可证下已发布或正在申请的合作专利的版税产生任何影响，因为这些许可证的当前版税率预计将超过新专利的到期时间。。

Webcast and Conference Call

网络广播和电话会议

Halozyme will discuss the new European patent and provide an update to its 2024 financial guidance and 5-year financial outlook on a conference call tomorrow, Thursday, June 6 at 5:30am PT/8:30am ET. The call will be webcast live through the 'Investors' section of Halozyme's corporate website and a recording will be made available following the completion of the call.

Halozyme将在明天（6月6日星期四上午5:30 PT/8:30 ET）的电话会议上讨论新的欧洲专利，并提供2024年财务指导和5年财务展望的最新信息。电话将通过Halozyme公司网站的“投资者”部分进行在线直播，通话结束后将提供录音。

To access the webcast and presentation, please visit ir.halozyme.com..

要访问网络广播和演示，请访问ir.halozyme.com。。

The call may also be accessed with the dial-in information below:

也可以使用以下拨入信息访问呼叫：

Participant Toll-Free Number: 888-632-3384

参与者免费电话：888-632-3384

Participant Direct/International Number: 785-424-1794

参与者直接/国际号码：785-424-1794

Conference ID: HALO0624

会议编号：HALO0624

About Halozyme

关于Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients.

Halozyme是一家生物制药公司，致力于推进颠覆性解决方案，以改善新兴和既定疗法的患者体验和结果。作为专有酶rHuPH20的ENHANZE®药物输送技术的创新者，Halozyme的商业验证解决方案用于促进注射药物和液体的皮下输送，目的是减轻患者的治疗负担。

Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals..

Halozyme已在全球100多个市场的7种商业化产品中使用了80多万名患者，并已将其ENHANZE®技术授权给领先的制药和生物技术公司，包括罗氏（Roche）、武田（Takeda）、辉瑞（Pfizer）、杨森（Janssen）、艾伯维（AbbVie）、礼来（Eli Lilly）、百时美施贵宝（Bristol-Myers Squibb）、阿根克斯（argenx）、维夫医疗（ViiV Healthcare）、楚盖制药（Chugai Ph。。

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.

Halozyme还使用其先进的自动注射器技术为自己或与合作伙伴开发，制造和商业化药物-装置组合产品，这些技术旨在提供商业或功能优势，例如改进的便利性，可靠性和耐受性，以及增强患者的舒适性和依从性。

The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals..

该公司拥有两种商业专有产品Hylenex®和XYOSTED®，与包括Teva Pharmaceuticals和Idorsia Pharmaceuticals在内的多家制药公司合作开发商业产品和正在进行的产品开发计划。。

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

Halozyme总部位于加利福尼亚州圣地亚哥，在新泽西州尤因和明尼苏达州明尼通卡设有办事处。明尼通卡也是其运营设施所在地。

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

有关更多信息，请访问www.halozyme.com，并通过LinkedIn和Twitter与我们联系。

Safe Harbor Statement

安全港声明

In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the recent grant of Halozyme's European Patent No. 4269578 covering Halozyme's ENHANZE® drug delivery technology rHuPH20 product including the expected validation of the patent in thirty-seven European countries, the future expected expiration date of the patent, the expected impact the patent will have on Halozyme's current and future ENHANZE® licenses, including the expected prevention of the reduction in the royalty rate Halozyme receives under the Janssen license on sales of products co-formulated with ENHANZE® in the European countries where the patent is validated. .

除历史信息外，本新闻稿中的声明还包括前瞻性声明，包括但不限于关于最近授予Halozyme欧洲专利号4269578的声明，该专利涵盖Halozyme的ENHANZE®药物输送技术rHuPH20产品，包括该专利在37个欧洲国家的预期验证，该专利的未来预期到期日，该专利对Halozyme当前和未来ENHANZE®许可的预期影响，包括预计防止Halozyme在Janssen许可下在与ENHANZE®共同配制的产品在专利验证的欧洲国家的销售中获得的版税率降低。。

These forward-looking statements are typically, but not always, identified through use of the words 'believe,' 'expected,' 'pending,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

这些前瞻性陈述通常（但并非总是）通过使用“相信”、“预期”、“待定”、“启用”、“可能”、“将”、“可能”、“打算”、“估计”、“预期”、“计划”、“预测”、“可能”、“潜在”、“可能”、“应该”、“继续”等类似含义的词语来识别，并涉及可能导致实际结果与前瞻性陈述中的结果产生重大差异的风险和不确定性。

Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected results or delays in the validation of the recently issued European patent in European countries and termination of the European patent prior to the expected date of expiration.

由于几个因素，实际结果可能与这些前瞻性声明中包含的预期存在重大差异，包括意外结果或在欧洲国家验证最近发布的欧洲专利的延迟以及在预期到期日之前终止欧洲专利。

These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty or obligation to update forward-looking statements to reflect events after the date of this press release..

Halozyme最近提交给美国证券交易委员会的10-K表年度报告和10-Q表季度报告中详细讨论了可能导致差异的这些因素和其他因素。除法律要求外，Halozyme没有义务或义务更新前瞻性声明以反映本新闻稿发布日期后的事件。。

Contacts:

联系人：

Tram Bui

电车Bui

VP, Investor Relations and Corporate Communications

投资者关系和企业传播副总裁

609-359-3016

609-359-3016

tbui@halozyme.com

tbui@halozyme.com

Samantha Gaspar

Samantha Gaspar

Teneo

特尼奥

212-886-9356

212-886-9356

samantha.gaspar@teneo.com

samantha.gaspar@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-issuance-of-new-european-patent-for-enhanze-drug-delivery-platform-302165251.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/halozyme-announces-issuance-of-new-european-patent-for-enhanze-drug-delivery-platform-302165251.html

SOURCE Halozyme Therapeutics, Inc.

来源Halozyme Therapeutics，Inc。

Company Codes: NASDAQ-NMS:HALO

公司代码：NASDAQ-NMS：HALO